![Dragan Cicic](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dragan Cicic
Corporate Officer/Principal chez
SELLAS LIFE SCIENCES GROUP, INC.
Fortune : 1 M $ au 31/05/2026
Profil
Dragan Cicic is currently a Member at the American Society of Hematology and Chief Development Officer & Senior Vice President at SELLAS Life Sciences Group, Inc. since 2024.
Former positions include Director, Chief Operating & Medical Officer at Actinium Pharmaceuticals, Inc. (2012–2013), Project Director at QED Technologies International, Inc., Chief Operating & Medical Officer at Cactus Ventures, Inc. (2012–2013), Principal at British Broadcasting Corp., Chief Technology Officer at Actinium Pharmaceuticals, Inc. (2017), and Senior Vice President at KLUS Pharma, Inc. Education includes a doctorate from the University of Belgrade, an MBA from The Wharton School of the University of Pennsylvania, and a doctorate from the School of Medicine (RS).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2026 | 126 443 ( 0,07 % ) | 1 M $ | 31/05/2026 |
Postes actifs de Dragan Cicic
| Sociétés | Poste | Début |
|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Corporate Officer/Principal | - |
American Society of Hematology
 American Society of Hematology Miscellaneous Commercial ServicesCommercial Services Operates as a hematology membership organisation | Corporate Officer/Principal | - |
Anciens postes connus de Dragan Cicic
| Sociétés | Poste | Fin |
|---|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | Directeur Général | - |
Actinium Pharmaceuticals, Inc. /Old/
 Actinium Pharmaceuticals, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Develops and commercializes alpha particle immunotherapeutics | Directeur Technique/Scientifique/R&D | 18/04/2013 |
Cactus Ventures, Inc.
 Cactus Ventures, Inc. Financial ConglomeratesFinance Operates as a blank check company | Directeur des opérations | 18/04/2013 |
KLUS Pharma, Inc.
 KLUS Pharma, Inc. BiotechnologyHealth Technology Engages in discovery and development of novel and safer antibody-based therapeutics | Corporate Officer/Principal | - |
British Broadcasting Corp.
 British Broadcasting Corp. BroadcastingConsumer Services Provides television and radio broadcasting & digital media services | Corporate Officer/Principal | - |
Formation de Dragan Cicic
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
60
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Actinium Pharmaceuticals, Inc. /Old/
Actinium Pharmaceuticals, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Develops and commercializes alpha particle immunotherapeutics | Commercial Services |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Operates as a blank check company | Finance |
British Broadcasting Corp.
British Broadcasting Corp. BroadcastingConsumer Services Provides television and radio broadcasting & digital media services | Consumer Services |
University of Belgrade
 University of Belgrade Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
QED Technologies International, Inc.
 QED Technologies International, Inc. SemiconductorsElectronic Technology Develops polishing and metrology technology for semiconductors | Electronic Technology |
American Society of Hematology
American Society of Hematology Miscellaneous Commercial ServicesCommercial Services Operates as a hematology membership organisation | Commercial Services |
Actinium Pharmaceuticals, Inc.
 Actinium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
School of Medicine (RS)
 School of Medicine (RS) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SELLAS Life Sciences Group, Inc.
 SELLAS Life Sciences Group, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
KLUS Pharma, Inc.
KLUS Pharma, Inc. BiotechnologyHealth Technology Engages in discovery and development of novel and safer antibody-based therapeutics | Health Technology |
